Table 4 Frequency of Prader–Willi syndrome (PWS) patients’ main characteristics in responsive, stable and non-responsive subjects at baseline.
Responsive | Stable | Non-responsive | Chi square | ||
|---|---|---|---|---|---|
24 (40%) | 17 (28%) | 19 (32%) | |||
Sex | M | 9 (38%) | 5 (29%) | 8 (42%) | 0.728 |
F | 15 (63%) | 12 (71%) | 11 (58%) | ||
Karyotype | del15 | 21 (88%) | 12 (71%) | 11 (58%) | 0.036 |
met + | 2 (8%) | 1 (6%) | 0 (0%) | ||
UPD | 1 (4%) | 4 (24%) | 8 (42%) | ||
Diabetes | Yes | 2 (8%) | 3 (18%) | 2 (11%) | 0.646 |
No | 22 (92%) | 14 (82%) | 17 (89%) | ||
Glycaemic therapy | Yes | 3 (13%) | 5 (29%) | 4 (21%) | 0.407 |
No | 21 (88%) | 12 (71%) | 15 (79%) | ||
Dyslipidaemia therapy | Yes | 0 (0%) | 0 (0%) | 1 (5%) | – |
No | 24 (100%) | 17 (100%) | 18 (95%) | ||
Antihypertensive therapy | Yes | 7 (29%) | 2 (12%) | 0 (0%) | 0.026 |
No | 17 (71%) | 15 (88%) | 19 (100%) | ||
Metabolic Syndrome | Yes | 11 (46%) | 7 (41%) | 6 (32%) | 0.634 |
No | 13 (54%) | 10 (59%) | 13 (68%) | ||
Smoke | Yes | 4 (17%) | 1 (6%) | 1 (5%) | 0.435 |
No | 20 (83%) | 16 (94%) | 15 (79%) | ||
GH therapy | Yes | 9 (38%) | 2 (12%) | 7 (37%) | 0.152 |
No | 15 (63%) | 15 (88%) | 12 (63%) |
